Federal Program Encourages Early Screening

ASHA Leader ◽  
2014 ◽  
Vol 19 (6) ◽  
pp. 12-12
2006 ◽  
Vol 34 (9) ◽  
pp. 45
Author(s):  
Diana Mahoney ◽  
CARL C. BELL
Keyword(s):  

Reflexio ◽  
2018 ◽  
Vol 11 (1) ◽  
pp. 47-67
Author(s):  
O. N. Pervushina ◽  
◽  
A. S. Kudrjavzeva ◽  
M. P. Mezentseva ◽  
◽  
...  
Keyword(s):  

Author(s):  
Konstantin R. Galkovich

This review summarizes the data on the diagnostic value of determining the fatty acid-binding protein (FABP) in urological and nephrological diseases. A physiological role of this protein in the pathogenesis of malignant neoplasms of the kidney, bladder, and prostate was analyzed. The dynamics of FABP in serum and urine with decreased renal function was studied: this protein is considered as a diagnostic and prognostic marker for chronic kidney disease and acute renal injury. The value of FABP for early screening of patients with obstructive nephropathy was revealed, and its role in predicting the restoration of kidney function was studied: the dynamics of FABP content can characterize the process of graft recovery, determine the need for hemodialysis. In patients with oligozooastenospermia, a reduced content of FABP in the ejaculate was registered, which was probably an adverse sign indicating a violation of male fertility.


2019 ◽  
Author(s):  
Dongqiong Ni ◽  
Bin Lv ◽  
Haibiao Bao ◽  
Haifeng Jin ◽  
Jing Zhao ◽  
...  

2020 ◽  
Author(s):  
Ponrathi Athilingam ◽  
Andrew Bugajski ◽  
Usha Menon

UNSTRUCTURED Chronic obstructive pulmonary disease (COPD) predominantly affects older adults, and claimed 3 million lives in 2016, making it the third leading cause of death worldwide. Over 35 million Americans aged 40 or older have lung function consistent with diagnosable COPD. COPD and cardiovascular disease (CVD) have a bidirectional relationship, in that one is a risk factor for developing the other. National and international consortiums recommend early screening of adults at risk of COPD, such as those with CVD. Recommended screening strategies include screening tools to assess symptoms, medical history, and handheld spirometry. Handheld spirometry has high diagnostic accuracy and if impaired lung function is indicated, these patients are referred for pulmonary function testing (PFT), the diagnostic gold standard for COPD. However, there is no clinical consensus for pulmonary screening in people with CVD. Current knowledge relating to the prevalence and incidence of CVD in people with COPD and the mechanisms that underlie their coexistence is key in combating the global burden of COPD.


Sign in / Sign up

Export Citation Format

Share Document